Two-part study of elective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 studying safety, tolerability, pharmacokinetics, and effects on human experimental pain in healthy volunteers

Trial Profile

Two-part study of elective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 studying safety, tolerability, pharmacokinetics, and effects on human experimental pain in healthy volunteers

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs LY 545694 (Primary)
  • Indications Musculoskeletal pain; Neuropathic pain
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 04 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top